New Blood Test Enables⁤ Rapid Diagnosis of Thousands of Rare Genetic ​Diseases

⁤ Updated ‌May 25, 2025

A ‍new proteomic ⁤test promises ​to revolutionize⁢ the diagnosis of rare ‌genetic diseases. The innovative approach requires only⁢ 1 milliliter ​of blood ​from infants⁣ and⁣ delivers results in less than‌ three​ days for ⁢patients in acute care, offering⁤ a important advancement ⁤in speed and efficiency.

The test ⁣analyzes more than 8,000 proteins in peripheral blood mononuclear cells (PBMCs), ‍covering over ⁢half ‍of known Mendelian⁤ and mitochondrial disease⁢ genes. Researchers hope this comprehensive‍ analysis will become⁢ standard in clinical labs,enhancing the ability to discover new disease genes and improve patient outcomes.

Dr. Hock, who ‌is involved in the test’s advancement, explained‌ that when blood samples from parents are included, it’s​ called trio analysis.⁤ This ⁣method⁤ is especially useful⁢ in ⁢recessively inherited ⁤conditions,helping​ to distinguish between carriers,who have one copy‌ of⁣ the defective gene,and affected individuals,who have ‌two copies.

For patients, a‍ swift molecular diagnosis means faster access to appropriate treatment, a clearer⁣ prognosis, and an ⁢end to numerous invasive tests. Families ​benefit from access to reproductive options, such as prenatal or preimplantation genetic ⁤testing, to prevent ‍future occurrences of the⁣ disease. ‍Health care systems could see reduced⁣ health care costs by replacing multiple ⁣targeted tests with‌ a single,‌ comprehensive analysis, enabling earlier ‍and more effective care.

A recent study,⁣ in collaboration with the Melbourne School of⁤ Population and Global Health,‌ indicated that implementing this new ‌test ‌would have a ⁢similar cost to current tests for‍ rare mitochondrial diseases. However, the new ⁢test has the potential to diagnose thousands of other⁣ diseases, according to​ Hock.

​ ⁤ “our new test can identify‍ more than⁣ 8,000 proteins in ‌peripheral blood mononuclear cells (PBMCs) ⁣covering more than 50% of known Mendelian and mitochondrial disease​ genes, as well as enable us to discover new​ disease genes,” dr. Hock said.

The⁣ researchers emphasize the revolutionary impact of using minimal​ blood from infants and​ producing robust results quickly.‌ The use of familial samples for trio ⁢analysis substantially improves the differentiation between carriers and ⁣affected individuals, exceeding ‌initial ‌expectations.

‍ “The ability​ to ‍use so little blood from infants and to produce robust​ results​ with a rapid turnaround time ‍has ⁢been revolutionary to⁢ families,” Dr. ⁢Hock said. ‌”Moreover, the use of familial samples for ⁣trio analysis greatly improves the differentiation​ between carrier and⁢ affected individuals with higher confidence,⁣ and that has ⁢exceeded our ⁤initial⁤ expectations. we believe that the use of⁤ this test‌ in clinical practice will ‌bring considerable benefits to patients, ⁣thier families and to⁤ health care systems by reducing the diagnostic time.”

Professor ⁤Alexandre Reymond, chair of the conference, highlighted⁢ the future potential of non-invasive​ agnostic approaches like genome sequencing and protein analysis. He said ⁢these ​methods will allow for more rapid diagnoses and solve previously unsolvable cases, benefiting ​families worldwide.

‌ “Non-invasive agnostic approaches such as genome sequencing and protein analysis will allow us to reach a diagnosis more rapidly in the future. They will also permit the solving of previously unsolvable cases,thus helping families worldwide,” Reymond said.

What’s next

Researchers aim for the ⁣proteomic test to become a⁣ standard ‍diagnostic procedure for rare and other genetic ⁣diseases‍ in ⁣clinical labs, promising considerable benefits to patients, families, and health care⁣ systems by reducing diagnostic time and improving care.